Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Chief Development Officer William Guyer of Corcept Therapeutics (NASDAQ:CORT) sold 20,000 shares of common stock on October 7, 2025, for a total of $1.79 million. The shares were sold at a weighted average price of $89.9391, with individual sales prices ranging from $89.85 to $90.18. The transaction comes as the stock has delivered impressive returns, up over 75% year-to-date, with InvestingPro analysis indicating the stock is currently trading above its Fair Value.
On the same day, Guyer also exercised options to acquire 20,000 shares of Corcept Therapeutics stock at an exercise price of $21.65, for a total value of $433000. This transaction was related to stock options with an expiration date of September 1, 2031. Following these transactions, Guyer directly owns 5,287 shares of Corcept Therapeutics, which now commands a market capitalization of $9.34 billion and maintains a "GREAT" financial health score according to InvestingPro’s comprehensive analysis.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted on November 27, 2024. For deeper insights into CORT’s valuation metrics and 15+ additional ProTips, explore the detailed Pro Research Report available exclusively on InvestingPro.
In other recent news, Corcept Therapeutics reported its second-quarter 2025 earnings, showcasing an earnings per share (EPS) of $0.29, which surpassed analyst expectations of $0.19 by 52.63%. However, the company’s revenue was slightly below predictions, coming in at $194.4 million compared to the anticipated $199.4 million. In regulatory developments, the U.S. Food and Drug Administration accepted Corcept’s New Drug Application for relacorilant as a treatment for platinum-resistant ovarian cancer, with a decision expected by July 11, 2026. Truist Securities reiterated its Buy rating on Corcept, maintaining a $135.00 price target, citing upcoming catalysts such as a court decision involving Teva and a PDUFA date for relacorilant. Additionally, Corcept is set to present data from its Phase 3 ROSELLA trial at the European Society for Medical Oncology Annual Meeting, focusing on relacorilant’s effects on ovarian cancer patients previously treated with PARP inhibitors. The company also announced the resignation of board member Gillian Cannon, who will continue to provide consulting services until the 2026 stockholders meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.